Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma

Dickran Kazandjian(United States Food and Drug Administration), Ola Landgren(University of Miami Health System), Constance M. Yuan(National Cancer Institute), Elisabet E. Manasanch(National Institutes of Health), Barış Türkbey(National Institutes of Health), Joseph Roswarski(Georgetown University), Jane B. Trepel(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Mark Roschewski(National Cancer Institute), Katherine R. Calvo(National Institutes of Health Clinical Center), Manisha Bhutani(Carolinas Healthcare System), Mary Kwok(National Cancer Institute), Min-Jung Lee(Center for Cancer Research), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Neha Korde(United States Fish and Wildlife Service), Alexander Dew(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Esther Mena(National Institutes of Health), Ani Petrosyan(National Institutes of Health), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Nisha Patel(National Institutes of Health), Peter L. Choyke(National Cancer Institute), Nishant Tageja(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Yong Zhang(National Institutes of Health), Sunmin Lee(National Institutes of Health), Elizabeth Hill(University of Maryland, Baltimore), Irina Marić(Center for Cancer Research), Michael Emanuel(National Institutes of Health), Alina Dulau‐Florea(National Institutes of Health), Candis Morrison(National Institutes of Health), Weixin Wang(Binzhou Medical University)
JAMA Oncology
September 16, 2021
Cited by 46


Related Papers